PLL Therapeutics appoints renowned ALS expert Philippe Corcia to scientific board
Ella Day | June 25, 2025 | Appointment | Research and Development | ALS Reference Centre, National ALS Motor Neuron Study Group, Neurology, PLL Therapeutics, amyotrophic lateral sclerosis (ALS), scientific board
PLL Therapeutics has appointed leading amyotrophic lateral sclerosis (ALS) researcher Philippe Corcia to its scientific board, marking a strategic move to advance its polypeptide delivery platform and the development of the world’s first blood biomarker for early detection of ALS.
Corcia, professor of neurology and head of the ALS Reference Centre in France since 2005, brings more than 30 years of clinical and research experience in ALS. He is president of the National ALS Motor Neuron Study Group and coordinates the FILSLAN network in France, with an extensive track record of over 300 publications and leadership roles in major ALS research consortia including ENCALS and TRICALS.
“We are extremely proud and privileged to welcome Philippe,” said Jean-Pascal Zambaux, co-founder and CEO of PLL Therapeutics. “His clinical insight and global network will be instrumental as we progress PLL001 through phase 1 and 2 trials and evaluate our biomarker test for early-stage ALS detection.”
The appointment follows the recent launch of PLL001’s multi-stage clinical trial. The therapy is based on a poly-targeted approach, using a polypeptide platform to deliver small chain fatty acids directly to the gut – targeting the gut-brain axis believed to be central to ALS pathology. The therapy aims to restore gut integrity and prevent toxin leakage into the bloodstream.
Corcia said: “I am intrigued by the elegance of PLL’s delivery platform and its potential to change the trajectory of ALS treatment. The prospect of a reliable blood biomarker for early diagnosis is particularly exciting.”
Founded in 2019, PLL Therapeutics is focused on treating autoimmune and neurodegenerative diseases through gut-focused interventions.
Ella Day
25/6/25
Related Content
PLL Therapeutics to present ALS research strategy at Bioshares Biotech Summit
French biotech, PLL Therapeutics, will present its approach to early detection and treatment of Amyotrophic …
